Symbols

STXS

Stereotaxis·AMEX

--(--)

STXS fundamentals

STXS Q4 2025 Earnings

Stereotaxis (STXS) released its earnings on Mar 9, 2026: revenue was 8.64M (YoY +36.31%), missed estimates; EPS was -0.06 (YoY +33.33%), beat estimates.

Revenue / YoY

8.64M

+36.31%

EPS / YoY

-0.06

+33.33%

Report date

Mar 9, 2026

STXS Earnings Call Summary for Q4,2025

Revenue Growth: FY2025 revenue up 20% to $32.4M, driven by MAGiC catheter sales ($5.3M/Q4).
Strategic Shift: Transitioning from $1k/procedure to $5k+/procedure with MAGiC, targeting $40M+ in 2026.
Key Products:
- GenesisX: 1 system sold in 2025, 5+ installations planned in 2026.
- MAGiC: 500+ catheters/month by year-end, $20M+ annual opportunity.
- Synchrony: $3M+ in 2026 from digital features and AI integrations.
Challenges: Manufacturing ramp for MAGiC (100+ catheters/month in Q1 2026), but confident in scaling.
China Expansion: MicroPort to sell Genesis systems (~$1M+ in 2026), transitioning to MAGiC for royalty revenue.

Earnings

EPS

Revenue

Revenue & Expenses

STXS has released its 2025 Q4 earnings report, with revenue of 8.64M, reflecting a YoY change of 36.31%, and net profit of -5.53M, showing a YoY change of 26.40%. The Sankey diagram below clearly presents STXS's revenue sources and cost distribution.

Key Indicators

Stereotaxis (STXS) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Stereotaxis (STXS)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Stereotaxis (STXS)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Stereotaxis (STXS)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown